ABBV · Categories · Downgrades
ABBV - Analyst downgrades
AbbVie Inc. (ABBV) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for ABBV
- AbbVie downgraded by Wolfe ResearchWolfe Research downgraded AbbVie from Outperform to Peer Perform
- AbbVie downgraded by DZ Bank with a new price targetDZ Bank downgraded AbbVie from Buy to Hold and set a new price target of $237.00
- AbbVie downgraded by Erste GroupErste Group downgraded AbbVie from Buy to Hold
- AbbVie downgraded by HSBC SecuritiesHSBC Securities downgraded AbbVie from Buy to Hold
- AbbVie downgraded by Citigroup with a new price targetCitigroup downgraded AbbVie from Buy to Neutral and set a new price target of $205.00
- AbbVie downgraded by Daiwa Securities with a new price targetDaiwa Securities downgraded AbbVie from Outperform to Neutral and set a new price target of $180.00
- AbbVie downgraded by HSBC SecuritiesHSBC Securities downgraded AbbVie from Buy to Hold
- AbbVie downgraded by ArgusArgus downgraded AbbVie from Buy to Hold
- AbbVie downgraded by Wolfe ResearchWolfe Research downgraded AbbVie from Outperform to Peer Perform
- AbbVie downgraded by Societe GeneraleSociete Generale downgraded AbbVie from Buy to Hold
- AbbVie downgraded by Atlantic Equities with a new price targetAtlantic Equities downgraded AbbVie from Overweight to Neutral and set a new price target of $162.00 from $178.00 previously
- AbbVie downgraded by Daiwa Securities with a new price targetDaiwa Securities downgraded AbbVie from Outperform to Neutral and set a new price target of $150.00
- AbbVie downgraded by UBS with a new price targetUBS downgraded AbbVie from Buy to Neutral and set a new price target of $147.00 from $129.00 previously